ReviewThe Lancet regional health. Southeast Asia2026
Reappraising TB preventive treatment in India: programmatic and ethical implications of subclinical tuberculosis in household contacts.
Review in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expanding the Frontiers of Tuberculosis Prevention: Moving from Targeted Preventive Therapy to Integrated Public Health Strategies.Tropical medicine and infectious disease · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India's pursuit of Tuberculosis (TB) elimination is contingent on the rapid universal scale-up of TB Preventive Treatment (TPT) for household contacts. However, current strategies largely neglect the asymptomatic active (subclinical) TB stage in terms of standardized diagnosis and optimized management. Consequently, administering TPT to individuals with unrecognized subclinical TB constitutes inadequate therapy that provides no patient benefit, enables community transmission, and risks minimal chances of iatrogenic drug resistance-violating the fundamental ethical principle of non-maleficence. We examine the tension between utilitarian public health goals and individual biomedical ethics, arguing for a transition within the National TB Elimination Program (NTEP) toward a rights-based framework prioritizing the clinical safety of household contacts. Crucially, the NTEP must institutionalize robust health education for contacts regarding the persistent risk of progression for at least 24 months post-TPT completion, coupled with sustained clinical surveillance to mitigate delayed health-seeking behavior. Further, sustained investment in digital diagnostics and translational research apart from addressing implementation gaps in the private sector is paramount to making TPT safe, evidence-driven, and ethically responsible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.